Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Soya bean oil, refined, Medium-chain triglycerides, Omega-3-acid triglycerides may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Lipidem is an emulsion of oils in water. The oils contained in Lipidem provide energy and contain essential fatty acids that are needed for your body to grow or recover. Lipidem is used to provide fat to patients needing to be fed by an intravenous drip, because they are unable to eat food normally or the normal intake is not enough. Lipidem is indicated in adults, preterm and term neonates, infants and toddlers, children and adolescents. 2.
Lipidem
Lipidem must NOT be used if one or more of the following conditions are present: if you are allergic to egg, fish, peanut, or soya-bean protein or any of the other ingredients of this medicine (listed in section 6). abnormally high blood fat level (severe hyperlipidaemia characterized by hypertriglyceridaemia) conditions where the blood does not clot properly (severe coagulopathy) impaired bile flow (intrahepatic cholestasis) severe liver failure (severe hepatic insufficiency) severe kidney failure (severe renal insufficiency) without access to treatment with an artificial kidney (haemofiltration or dialysis) blocking of blood vessels by blood clots or fat (acute thromboembolic events, fat embolism) abnormally high level of acidic substances in the blood (acidosis) Patients must generally not receive artificial nutrition via intravenous drip (parenteral nutrition) if one or more of the following conditions are present:
041805KM0520H19
–
life-threatening blood circulation problems such as those that can occur if you are in a state of collapse or shock acute phase of heart attack (cardiac infarction) or stroke unstable metabolism, for example because of diabetes mellitus, infections involving the whole body (severe sepsis), or coma of unknown origin insufficient supply of oxygen to tissues disturbances of your body salt composition fluid deficit or excess water in the body water in the lungs (acute pulmonary oedema) severe heart failure (decompensated cardiac insufficiency)
Warnings and precautions Talk to your doctor before you are given Lipidem. Monitoring During infusion, the amount of fat (serum triglycerides) in your blood should be monitored by your doctor. If your blood fat values rises too high, your doctor may reduce the infusion speed or stop the infusion. While you receive this solution, your doctor should check your levels of fluids, blood salts and the acidbase balance. Your liver and kidney function and your blood clotting function should be monitored and blood cell counts should be performed. If you show signs of an allergic reaction – such as fever, shivering, rash, or breathing problems – when you receive this medicine, the infusion should be stopped immediately by your doctor. Additional measures Before you receive this medicine any existing disorders of your body's fluid and salt content as well as disturbances of your acid-base balance will be corrected by your doctor. In addition to Lipidem you may receive a carbohydrate solution and an amino acid solution to prevent metabolic conditions where your blood becomes acidic (metabolic acidosis). To make your intravenous feeding complete, you may also receive carbohydrate solutions and amino acid solutions. The nursing staff may also take measures to ensure that your body's fluid, electrolyte, vitamin and trace element requirements are met. Elderly patients In some conditions your ability to use fat correctly may be impaired. Your doctor will keep in mind that some of these conditions are frequently associated with advanced age, e.g. impaired heart or kidney function. Patients with heart or kidney problems If you have heart or kidney problems, your doctor will be especially careful when giving you this medicine. Patients with impaired lipid metabolism In some conditions your ability to use fat correctly may be impaired and your blood fat values may be too high. Therefore, it is important that your doctor knows: if you have diabetes mellitus if you have an inflammation of the pancreas (pancreatitis) if you have impaired liver or kidney function (renal insufficiency, impaired hepatic function) if you have a reduced activity of the thyroid gland (hypothyroidism) if you have blood poisoning (sepsis)
041805KM0520H19
–
if you have a condition where you may have a combination of 3 or more of the following: an increase in fat around your abdomen, a decrease in "good cholesterol" (HDL-C), an increase in your blood fat, high blood pressure and an increase in your blood sugar (metabolic syndrome) If your ability to use fat correctly is impaired, your doctor should monitor your blood fat (serum triglyceride) levels very closely. Children and adolescents In infants at risk of jaundice the blood fat (serum triglyceride) and bilirubin levels should be monitored by your doctor. It may become necessary for your doctor to adjust the daily fat doses. During infusion this solution should be protected from the light of a phototherapy to decrease the formation of potentially harmful substances (triglyceride hydroperoxides). When used in neonates and children below 2 years, the solution (in bottles and administration sets) should be protected from light exposure until administration is completed. Exposure of Lipidem to ambient light, especially after admixtures with trace elements and/or vitamins, generates peroxides and other degradation products that can be reduced by protection from light exposure. Other medicines and Lipidem Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Lipidem may interact with some other medicines. Tell your doctor if you are taking or receiving certain medicines that prevent undesirable blood clotting, namely ● heparin ● coumarin products, for example warfarin. It may be necessary to check the clotting of your blood by taking regular blood samples. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine. Pregnancy If you are pregnant you will receive this medicine only if the doctor considers it absolutely necessary for your recovery. There is no data about the use of Lipidem in pregnant women. Breast-feeding Breast-feeding is not recommended for mothers on parenteral nutrition. Driving and using machines You will receive this medicine in a controlled setting, i.e. a hospital or under any other kind of medical supervision, which normally excludes driving or using machines. Lipidem contains sodium This medicine contains 59.8 mg sodium (main component of cooking/table salt) in 1000 ml. This is equivalent to 3 % of the recommended maximum daily dietary intake of sodium for an adult.
041805KM0520H19
3.
Lipidem
Dosage Your doctor will decide how much of this medicine you need and for how long you will require treatment with this medicine. The daily doses will be adjusted to your needs, your age and your body weight. The doses are normally calculated on a "gram of fat per kg body weight" basis. Care will be taken that the doses and infusion rates used are correct for you, so your body's capacity to use the infused fat will not be exceeded. How is Lipidem given? Lipidem will be given by an intravenous drip as part of a feeding programme. For this purpose a tube (catheter) will be inserted into a vein, through which the fat emulsion can either be given separately or together with other fluids. When used in neonates and children below 2 years, the solution (in bottles and administration sets) should be protected from light exposure until administration is completed (see section 2). If you received more Lipidem than you should If you have received too much Lipidem you may get abnormally high blood fat levels (hyperlipidaemia), your blood may become too acidic (metabolic acidosis) or you may suffer from a so-called "fat overload syndrome". For symptoms of the fat overload syndrome please see section 4 "Possible side effects". If you have received too much Lipidem, the infusion will be stopped immediately. The infusion will not be started again until you have recovered. It may be necessary for your doctor to adjust the daily fat doses. Your doctor will decide on any additional treatment. If you have any further questions on the use of this product, ask your doctor or pharmacist. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may be serious. If any of the following side effects occur, contact your doctor immediately, they will stop giving you this medicine: Very rare: may affect up to 1 in 10,000 people allergic reactions, for example skin reactions, shortness of breath, swelling of the lips, mouth and throat, difficulty breathing breathing problems (dyspnoea) bluish skin (cyanosis) Other side effects include Very rare: may affect up to 1 in 10,000 people fat overload syndrome (see "Fat overload syndrome" below) increased tendency of your blood to clot (hypercoagulation)
041805KM0520H19
–
abnormally high blood fat levels (hyperlipidaemia) abnormally high blood sugar levels (hyperglycaemia) high levels of acidic substances in your blood (metabolic acidosis) decrease or increase in blood pressure drowsiness feeling sick, vomiting, loss of appetite headache flushing reddening of the skin (erythema) fever sweating feeling cold, chills
Rare: may affect up to 1 in 1,000 people pain in the back, bones, chest and lumbar region Not known: frequency cannot be estimated from the available data impaired bile flow (cholestasis) reduction of white blood cell count (leucopenia) reduction of blood platelet count (thrombocytopenia) If you get any of these side effects, the infusion will be stopped. Fat overload syndrome: You might suffer from a "fat overload syndrome" if you have received too much Lipidem or when your body has problems using fat. Your body's ability to use fat might be influenced by a sudden change in your condition (due to renal problems or an infection). The symptoms are usually reversible if the infusion is stopped. A fat overload syndrome is characterised by the following symptoms: –
high blood fat levels (hyperlipidaemia) fever deposition of fat in the liver or other organs (fat infiltration) enlargement of the liver (hepatomegaly), which may sometimes be accompanied by jaundice (icterus) enlargement of the spleen (splenomegaly) reduction of red blood cell count (anaemia) reduction of white blood cell count (leucopenia) reduction of blood platelet count (thrombocytopenia) disorder of blood clotting (coagulation disorder) rupture of blood cells (haemolysis) increase in immature red blood cells (reticulocytosis) abnormal liver function tests loss of consciousness (coma)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
041805KM0520H19
5.
Lipidem
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and the outer carton. The expiry date refers to the last day of that month. After first opening Lipidem should be used immediately. Do not store above 25 °C. Keep the container in the outer carton in order to protect from light. Do not freeze. Products that have been frozen must be discarded. Do not use this medicine if you notice: large oil drops in the emulsion or two separate layers of fluid discoloration damage of the container or the closure. When used in neonates and children below 2 years, the solution (in bottles and administration sets) should be protected from light exposure until administration is completed (see section 2). 6.
Content of the pack and other information
What Lipidem contains
7990 (1910) 410 < 0.5 6.0- 8.5
041805KM0520H19
It is supplied in glass bottles with rubber stoppers, pack sizes: 10 × 100 ml, 10 × 250 ml, 10 × 500 ml, Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer
B. Braun Melsungen AG Carl-Braun-Straße 1 34212 Melsungen, Germany Postal address 34209 Melsungen, Germany This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (GB and NI) under the following names: Austria:
Lipidem Emulsion zur Infusion
Czech Republic: Germany: Denmark:
Lipoplus 20% Lipidem Emulsion zur Infusion Lipidem
Spain: Finland: France:
Lipoplus 20% Lipoplus 200 mg/ml Lipidem 200 mg/ml
United Kingdom (GB and NI):
Lipidem 200 mg/ml Emulsion for Infusion
Italy: Luxembourg:
Lipidem 200 mg/ ml Lipidem
Norway: Poland: Portugal: Sweden: Slovakia:
Lipidem Lipidem Lipoplus Lipoplus Lipoplus 20%
This leaflet was last revised in January 2026 ————————————————————————————————————————–The following information is intended for healthcare professionals only: Method of administration and special precautions for disposal and other handling Intravenous use.
041805KM0520H19
Lipid emulsions are suitable for peripheral venous administration and can also be administered separately via peripheral veins as part of total parenteral nutrition. The Y- or the bypass connector should be placed as close to the patient as possible if lipid emulsions are coadministered with amino acid and carbohydrate solutions. When used in neonates and children below 2 years, the solution (in bottles and administration sets) should be protected from light exposure until administration is completed. For single use only. Container and unused residues must be discarded after use. Do not reconnect partially used containers. Shake gently prior to use. Only use containers that are undamaged and in which the emulsion is homogeneous and milky-white. Inspect the emulsion visually for phase separation and discoloration prior to administration (oil drops, oil layer). The emulsion has to be brought to room temperature unaided prior to infusion, i.e., the product should not be put in a heating device (such as oven or microwave). If filters are used, these must be permeable to lipids. Before infusing a lipid emulsion together with other solutions via a Y connector or bypass set, the compatibility of these fluids should be checked, especially when co-administering carrier solutions to which drugs have been added. Particular caution should be taken when co-infusing solutions that contain divalent cations (such as calcium or magnesium). Special precautions for disposal and other handling When used in neonates and children below 2 years, protect from light exposure, until administration is completed. Exposure of Lipidem mg/ml to ambient light, especially after admixtures with trace elements and/or vitamins, generates peroxides and other degradation products that can be reduced by protection from light exposure. Duration of treatment As clinical experience with long-term use of Lipidem is limited, it should normally not be administered for longer than one week. If parenteral nutrition with lipid emulsions is further indicated, Lipidem can be administered over longer periods provided appropriate monitoring is employed. Infusion rate The infusion should be administered at the lowest possible infusion rate. During the first 15 minutes the infusion rate should only be 50% of the maximum infusion rate to be used. Maximum infusion rate for adults Up to 0.15 g/kg b.w./h lipids. Maximum infusion rate for preterm newborn infants, term newborn infants, infants and toddlers Up to 0.15 g/kg b.w./h lipids. Maximum infusion rate for children and adolescents Up to 0.15 g/kg b.w./h lipids. Interference with laboratory tests
041805KM0520H19
Lipids may interfere with certain laboratory tests (such as bilirubin, lactate dehydrogenase, oxygen saturation) when the blood sample is taken before the lipids have been eliminated from the bloodstream, this may take 4 to 6 hours. Incompatibilities In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Shelf life after admixture of compatible additives From a microbiological point of view, the product should be used immediately after admixture of additives. If not used immediately after admixture of additives, in-use storage times and conditions prior to use are the responsibility of the user. For full information on this product please refer to the Summary of Product Characteristics of Lipidem. Special warnings and precautions for use Light exposure of solutions for intravenous parenteral nutrition, especially after admixture with trace elements and/or vitamins, may have adverse effects on clinical outcome in neonates, due to generation of peroxides and other degradation products. When used in neonates and children below 2 years, Lipidem should be protected from ambient light until administration is completed.
041805KM0520H19
Lipidem 200 mg/ml emulsion for infusion comes as infusion containing 200mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Lipidem 200 mg/ml emulsion for infusion is soya bean oil, refined, medium-chain triglycerides, omega-3-acid triglycerides.
This leaflet reproduces the patient information leaflet approved for Lipidem 200 mg/ml emulsion for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Supply of energy, including a readily utilisable lipid component (medium-chain triglycerides) and essential omega-6 fatty acids and omega-3 fatty acids, as part of parenteral nutrition when oral or enteral nutrition is impossible, insufficient or contraindicated.
Lipidem 200mg/ml is indicated in adults, preterm and term neonates, infants and toddlers, children and adolescents.
Posology
The dosage has to be adapted to the patients' individual requirements.
Maximum daily doses should only be administered after stepwise increase with careful monitoring of the tolerance of the infusions.
The utilisation of intravenous lipids depends on e.g. the severity of underlying disease, body weight, gestational and postnatal age and specific body functions.
Depending on energy requirements, the following daily doses are recommended:
Adults
The usual dose is 0.7 to 1.5 g lipids/kg body weight (b.w.) per day. A maximum dose of 2.0 g lipids/kg b.w./d, for instance when energy requirements are high or fat utilisation is increased (e.g. oncology patients), should not be exceeded For long-term home parenteral nutrition treatment (> 6 months) and in patients with short bowel syndrome the provision of intravenous lipids should not exceed 1.0 g/kg b.w./d.
For a patient weighing 70 kg a daily dose of 2.0 g/kg b.w./d corresponds to a maximum daily dose of 700 ml Lipidem 200mg/ml.
Paediatric population
A gradual increase of lipid intake in increments of 0.5 – 1.0 g/kg b.w./d may be beneficial regarding the possibility to monitor the increase of the plasma triglyceride level and prevent hyperlipidaemia.
Preterm newborn infants, term newborn infants, infants and toddlers
It is recommended not to exceed a daily dose of 2.0 – 3.0 g/kg b.w./d of lipids.
In preterm newborn infants, term newborn infants, infants and toddlers, the daily dose of lipids should be infused continuously over about 24 hours.
Children and adolescents
It is recommended not to exceed a daily lipid dose of 2.0 – 3.0 g/kg b.w./d.
Elderly patients
Basically the same dosage as for adults applies, but caution should be exercised in patients suffering from further diseases like cardiac insufficiency or renal insufficiency that may frequently be associated with advanced age.
Patients with diabetes mellitus, impaired cardiac or renal function
See section 4.4.
Patients with hepatic impairment
See section 4.4 ('('Patients with impaired lipid metabolism').
Infusion rate
The infusion should be administered at the lowest possible infusion rate. During the first 15 minutes the infusion rate should only be 50% of the maximum infusion rate to be used.
The patient should be monitored closely for the occurrence of adverse reactions.
Maximum infusion rate
Adults
Up to 0.15 g/kg b.w./h lipids.
For a patient weighing 70 kg this corresponds to a maximum infusion rate of 52.5 ml per hour Lipidem 200mg/ml . The amount of lipids administered then is 10.5 g per hour.
Preterm newborn infants, term newborn infants, infants and toddlers
Up to 0.15 g/kg b.w./h lipids.
Children and adolescents
Up to 0.15 g/kg b.w./h lipids.
Method of administration
Intravenous use.
Lipid emulsions are suitable for peripheral venous administration and can also be administered separately via peripheral veins as part of total parenteral nutrition.
The Y- or the bypass connector should be placed as close to the patient as possible if lipid emulsions are co-administered with amino acid and carbohydrate solutions. For further instructions on handling of the medicinal product before administration, see section 6.6.
When used in neonates and children below 2 years, the solution (in bottles and administration sets) should be protected from light exposure until administration is completed (see sections 4.4, 6.3 and 6.6).
Duration of treatment
As clinical experience with long-term use of Lipidem 200mg/ml is limited, it should normally not be administered for longer than one week. If parenteral nutrition with lipid emulsions is further indicated, Lipidem 200mg/ml can be administered over longer periods provided appropriate monitoring is employed.
– Hypersensitivity to the active substances, to egg, fish, peanut or soya protein or to any of the excipients listed in section 6.1
– Severe hyperlipidaemia characterized by hypertriglyceridaemia (≥ 1000 mg/dl or 11.4 mmol/l)
– Severe coagulopathy
– Intrahepatic cholestasis
– Severe hepatic insufficiency
– Severe renal insufficiency in absence of renal replacement therapy
– Acute thromboembolic events, fat embolism
– Acidosis
General contraindications to parenteral nutrition include:
– Unstable circulatory status with vital threat (states of collapse and shock)
– Acute phases of cardiac infarction or stroke
– Unstable metabolic conditions (e.g. decompensated diabetes mellitus, severe sepsis, coma of unknown origin)
– Inadequate cellular oxygen supply
– Disturbances of the electrolyte and fluid balance
– Acute pulmonary oedema
– Decompensated cardiac insufficiency
The serum triglyceride concentration should be monitored when infusing Lipidem 200mg/ml.
In patients with suspected disorders of lipid metabolism, fasting hyperlipidaemia should be ruled out before the start of the infusion.
Depending on the patient's metabolic condition, occasional hypertriglyceridaemia may occur. If the plasma triglyceride concentration exceeds 4.6 mmol/l (400 mg/dl) in adults during administration of lipids it is recommended to reduce the infusion rate. The infusion must be interrupted if the plasma triglyceride concentration exceeds 11.4 mmol/l (1000 mg/dl), as these levels have been associated with an increased risk for acute pancreatitis.
Disturbances of the fluid, electrolyte or acid-base balance must be corrected before the start of infusion.
Refeeding or repletion of malnourished or depleted patients may cause hypokalaemia, hypophosphataemia and hypomagnesaemia. Adequate supplementation of electrolytes according to deviations from normal values is necessary.
Controls of the serum electrolytes, the water balance, the acid-base balance, and of blood cell counts, coagulation status, hepatic and renal function are necessary.
Any sign or symptom of anaphylactic reaction (such as fever, shivering, rash or dyspnoea) should lead to immediate interruption of the infusion.
Energy supply with lipid emulsions only could cause metabolic acidosis. It is therefore recommended to infuse an adequate quantity of intravenous carbohydrates or carbohydrate-containing amino acid solutions along with the fat emulsion.
For patients requiring complete parenteral nutrition, complementary carbohydrate, amino acid, electrolyte, vitamin, and trace element supplements are required. Also, an adequate total fluid intake has to be ensured.
Impaired capacity to eliminate triglycerides can lead to “fat overload syndrome” which may be caused by overdose (see section 4.8 and 4.9.).
Mixing with incompatible substances might lead to breaking of the emulsion or to precipitation of particles (see sections 6.2 and 6.6), both resulting in a high risk of embolism.
There is as yet only limited experience of the use of Lipidem 200mg/ml for periods longer than seven days.
As with all intravenous solutions, especially for parenteral nutrition, strict aseptic precautions are necessary for the infusion of Lipidem 200mg/ml.
Patients with diabetes mellitus, impaired cardiac or renal function
Like all large-volume infusion solutions, Lipidem 200mg/ml should be administered with caution to patients with impaired cardiac or renal function.
There is only limited experience of its use in patients with diabetes mellitus or renal failure.
Patients with impaired lipid metabolism
Lipidem 200mg/ml should be administered cautiously to patients with disturbances of lipid metabolism with increased serum triglycerides, e.g. renal insufficiency, diabetes mellitus, pancreatitis, impaired hepatic function, hypothyroidism (with hypertriglyceridaemia), sepsis, and metabolic syndrome. If Lipidem 200mg/ml is given to patients with these conditions, more frequent monitoring of serum triglycerides is necessary to assure triglyceride elimination and stable triglyceride levels below 11.4 mmol/l (1000 mg/dl).
In combined hyperlipidaemias and in metabolic syndrome, triglyceride levels react to glucose, lipids and overnutrition. Adjust dose accordingly. Assess and monitor other lipid and glucose sources, and drugs interfering with their metabolism.
The presence of hypertriglyceridaemia 12 hours after the administration of lipids also indicates disturbance of lipid metabolism.
Paediatric population
Free fatty acids (FFA) compete with bilirubin for albumin binding sites. Especially very premature infants may be at increased risk of hyperbilirubinaemia due to high levels of FFA released from triglycerides resulting in a high FFA/albumin ratio. In parenterally fed infants at risk of hyperbilirubinaemia, serum triglyceride and bilirubin levels should be monitored and lipid infusion rate be adjusted if deemed necessary.
During infusion Lipidem 200mg/ml should be protected from phototherapy light to decrease the formation of potentially harmful triglyceride hydroperoxides.
The serum triglyceride concentration should be regularly monitored during the infusion of Lipidem 200mg/ml, (especially in very small preterm infants), especially if there is an increased risk of hyperlipidaemia (e.g. in situations of stress or infection). A stepwise increase of the daily dose may be advisable.
Depending on the patient's metabolic condition, occasional hypertriglyceridaemia may occur. In infants dose reduction should be considered if the plasma triglyceride concentration during infusion exceeds 2.8 mmol/l (250 mg/dl). In older children and adolescents dose reduction should be considered if the plasma triglyceride concentration during infusion exceeds 4.6 mmol/l (400 mg/dl).
Light exposure of solutions for intravenous parenteral nutrition, especially after admixture with trace elements and/or vitamins, may have adverse effects on clinical outcome in neonates, due to generation of peroxides and other degradation products. When used in neonates and children below 2 years, Lipidem 200mg/ml should be protected from ambient light until administration is completed (see sections 4.2, 6.3 and 6.6).
Special warnings/precautions regarding excipients
This medicinal product contains 59.8 mg sodium per 1000 ml, equivalent to 3 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Interference with laboratory tests
Lipids may interfere with certain laboratory tests (such as bilirubin, lactate dehydrogenase, oxygen saturation) when the blood sample is taken before the lipids have been eliminated from the bloodstream, this may take 4 to 6 hours.
No interaction studies have been performed.
Heparin given in clinical doses causes a transient release of lipoprotein lipase into the bloodstream. This may initially lead to increased plasma lipolysis, followed by a transient decrease in triglyceride clearance.
Soya-bean oil has a natural content of vitamin K1. This may interfere with the therapeutic effect of coumarin derivatives, which should be closely monitored in patients treated with such drugs.
Pregnancy
There are no or limited amount of data from the use of Lipidem 200mg/ml in pregnant women. Animal studies undertaken with a lipid emulsion containing twice the amount of omega-3 acid triglycerides and a correspondingly smaller amount of omega-6-acid triglycerides as compared to Lipidem 200mg/ml do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
Parenteral nutrition may become necessary during pregnancy. Lipidem 200mg/ml should only be administered to pregnant women after careful benefit-risk consideration.
Breastfeeding
Components/metabolites of Lipidem 200mg/ml are excreted in human milk, but at therapeutic doses of Lipidem 200mg/ml no effects on the breastfed newborns/infants are anticipated. In general, breastfeeding is not recommended to mothers on parenteral nutrition.
Fertility
No data from the use of Lipidem 200mg/ml available.
Not relevant.
The following listing includes a number of systemic adverse reactions that may be associated with the use of Lipidem 200mg/ml. Under the conditions of correct use, in terms of dosing, monitoring, observation of safety restrictions and instructions, most of them are very rare (< 1/10,000).
Undesirable effects are listed according to their frequencies as follows:
Very common
Common
Uncommon
Rare
Very rare
Not known
(≥ 1/10)
(≥ 1/100 to < 1/10)
(≥ 1/1,000 to < 1/100)
(≥ 1/10,000 to < 1/1,000)
(< 1/10,000)
(cannot be estimated from the available data)
Blood and lymphatic system disorders
Very rare:
Hypercoagulation
Not known:
Leucopenia, thrombocytopenia
Immune system disorders
Very rare:
Allergic reactions (e.g. anaphylactic reactions, dermal eruptions, laryngeal, oral and facial oedema)
Metabolism and nutrition disorders
Very rare:
Hyperlipidaemia, metabolic acidosis
The frequency of these adverse reactions is dose-dependent and may be higher under conditions of absolute or relative overdose.
Very rare:
Hyperglycaemia
Nervous system disorders
Very rare:
Headache, drowsiness
Vascular disorders
Very rare:
Hypertension or hypotension, flush
Respiratory, thoracic and mediastinal disorders
Very rare:
Dyspnoea, cyanosis
Gastrointestinal disorders
Very rare:
Nausea, vomiting, loss of appetite
Skin and subcutaneous tissue disorders
Very rare:
Erythema, sweating
Hepatobiliary disorders
Not known:
Cholestasis
Musculoskeletal and connective tissue disorders
Rare:
Back, bones, chest and lumbar region pain
General disorders and administration site conditions
Very rare:
Elevated body temperature, feeling cold, chills, fat overload syndrome (see below).
Should adverse reactions occur, the infusion must be stopped.
Should the triglyceride level rise to above 11.4 mmol/l (1000 mg/dl) during infusion, the infusion must be stopped. With levels above 4.6 mmol/l (400 mg/dl), the infusion may be continued at a reduced dosage (see section 4.4).
If the infusion is restarted, the patient should be carefully monitored, especially at the beginning, and serum triglycerides should be determined at short intervals.
Information on particular undesirable effects
Nausea, vomiting and lack of appetite are symptoms often related to conditions for which parenteral nutrition is indicated, and may be associated with parenteral nutrition at the same time.
Fat overload syndrome
Impaired capacity to eliminate triglycerides can lead to “fat overload syndrome” which may be caused by overdose. Possible signs of metabolic overload must be observed. The cause may be genetic (individually different metabolism) or the fat metabolism may be affected by ongoing or previous diseases. This syndrome may also appear during severe hypertriglyceridaemia, even at the recommended infusion rate, and in association with a sudden change in the patient's clinical condition, such as renal function impairment or infection. The fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly with or without icterus, splenomegaly, anaemia, leucopenia, thrombocytopenia, coagulation disorder, haemolysis and reticulocytosis, abnormal liver function tests and coma. The symptoms are usually reversible if the infusion of the fat emulsion is discontinued.
Should signs of a fat overload syndrome occur, the infusion of Lipidem 200mg/ml must be discontinued immediately.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Symptoms
Hyperlipidaemia, metabolic acidosis.
Also, a fat overload syndrome may occur. See section 4.8.
Treatment
Immediate cessation of infusion is indicated for overdose. Other therapeutic measures will depend on a patient's specific symptoms and their severity. When the infusion is recommenced after symptoms have declined, it is recommended that the infusion rate should be raised gradually with monitoring at frequent intervals.
Ask anything about Lipidem 200 mg/ml emulsion for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.